Other formats:
BibTeX
LaTeX
RIS
@article{1312134,
author = {Kubackova, Katerina and Bortlíček, Zbyněk and Pavlík, Tomáš and Melichar, B. and Linke, Z. and Pokorna, P. and Vyzula, Rostislav and Prausova, J. and Buchler, T.},
article_location = {Dordrecht},
article_number = {3},
doi = {http://dx.doi.org/10.1007/s11523-014-0343-8},
keywords = {Renal cell carcinoma; Metastasis; Targeted therapy; Outcomes; First-line therapy},
language = {eng},
issn = {1776-2596},
journal = {Targeted Oncology},
title = {Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry},
volume = {10},
year = {2015}
}
TY - JOUR
ID - 1312134
AU - Kubackova, Katerina - Bortlíček, Zbyněk - Pavlík, Tomáš - Melichar, B. - Linke, Z. - Pokorna, P. - Vyzula, Rostislav - Prausova, J. - Buchler, T.
PY - 2015
TI - Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry
JF - Targeted Oncology
VL - 10
IS - 3
SP - 385-392
EP - 385-392
PB - Springer
SN - 17762596
KW - Renal cell carcinoma
KW - Metastasis
KW - Targeted therapy
KW - Outcomes
KW - First-line therapy
N2 - The aim of this study was to describe the characteristics and outcomes of a large cohort of patients treated with sorafenib in clinical practice and to identify predictive factors associated with prognosis. Patient data were obtained from the national Czech registry (RenIS). Data of virtually all Czech patients receiving targeted therapies are entered into this non-interventional post-registration database. Demographics and clinical data, as well as all treatment sequences and clinical outcomes, are reported in this registry. A total of 836 patients treated with sorafenib before March 2013 were included in the analysis. Median age was 63 years and 70 % were men. Most patients had received prior treatment with cytokines, sunitinib or both. Sorafenib was the first-line treatment in 15 % of patients. Median overall survival and progression-free survival were 21.7 months and 7.5 months, respectively. Median overall survival and progression-free survival was 26.3 and 8.3 months, respectively, in patients receiving sorafenib as first-line therapy. Cox proportional models identified several parameters associated with poor outcome including time a parts per thousand currency sign1 year from diagnosis to first-line systemic treatment, performance status a parts per thousand yen2, low hemoglobin, and LDH > 1.5 times the upper limit of normal. Our data demonstrate that the outcomes of real-life patients are comparable to those enrolled in clinical trials. Prognostic factors identified in the present study were consistent with previously reported models.
ER -
KUBACKOVA, Katerina, Zbyněk BORTLÍČEK, Tomáš PAVLÍK, B. MELICHAR, Z. LINKE, P. POKORNA, Rostislav VYZULA, J. PRAUSOVA and T. BUCHLER. Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry. \textit{Targeted Oncology}. Dordrecht: Springer, 2015, vol.~10, No~3, p.~385-392. ISSN~1776-2596. Available from: https://dx.doi.org/10.1007/s11523-014-0343-8.
|
